ストックスクリーナーアプリを入手
2.72
0.74%
0.02
アフターアワーズ：
2.72
Vyne Therapeutics Inc (VYNE) 最新ニュース
VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks
VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VYNE Therapeutics Reports Strong Pipeline Progress, $70.2M Cash Position Despite Q3 Loss | VYNE Stock News - StockTitan
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World
(VYX) Long Term Investment Analysis - Stock Traders Daily
Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat
ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks
ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks
Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga
What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News
Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha
Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World
A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily
HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE reports positive early trial results for inflammation drug - Investing.com
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks
VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
VYNE Therapeutics to Participate in September Investor Conferences - StockTitan
VYNE Therapeutics sees cash runway through end of 2025 - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace
Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way? - Simply Wall St
VYNE Therapeutics secures UK patent for inflammation drug - Investing.com
Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance
VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia
VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St
VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World
Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewswire Inc.
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo News UK
Eventide Asset Management LLC Takes $3.25 Million Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences - Investing.com India
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Canada
VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright - Defense World
Analyst Scoreboard: 4 Ratings For VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE) - Benzinga
Fostering Mentorship and Support in Early-Stage Physician Assistants - Dermatology Times
VYNE Therapeutics Initiates Phase 2b Trial of BET Inhibitor VYN201 for Vitiligo - Dermatology Times
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - Defense World
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):